William Blair Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating
William Blair has reiterated its Buy rating for TYRA BIOSCIENCES, INC. (TYRA.US). The report indicates continued confidence in the company's prospects.
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY
Tyra Biosciences and the Bladder Cancer Advocacy Network (BCAN) have partnered to designate May 21 as Upper Tract Urothelial Cancer (UTUC) Awareness Day. This initiative aims to increase awareness, amplify patient voices, and highlight the need for research and innovation in treating UTUC, a rare and difficult-to-treat cancer with limited effective options. Tyra Biosciences is currently developing dabogratinib, an investigational oral FGFR3-selective inhibitor, as a potential kidney-sparing treatment for low-grade UTUC.
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY
Tyra Biosciences and the Bladder Cancer Advocacy Network (BCAN) have partnered to establish May 21st as Upper Tract Urothelial Cancer (UTUC) Awareness Day. This initiative aims to increase awareness, amplify patient experiences, and encourage research into UTUC, a rare and difficult-to-treat cancer with limited systemic standard of care. Tyra Biosciences is currently developing dabogratinib, an investigational oral FGFR3-selective inhibitor, as a potential kidney-sparing treatment for low-grade UTUC.
Assessing Tyra Biosciences (TYRA) Valuation After Wider Losses And Progress In Dabogratinib Trials
Tyra Biosciences (TYRA) is under scrutiny after reporting wider losses but showing progress in its dabogratinib trials and attracting new institutional interest. Despite recent stock dips, TYRA has seen significant year-to-date and one-year returns, driven by its pipeline. The company trades at a Price-to-Book ratio of 5.2x, which is high compared to the broader US biotech industry but lower than its direct peers, suggesting a premium on its drug pipeline and cash.
Wolfe Research initiates coverage of Tyra Biosciences (TYRA) with peer perform recommendation
Wolfe Research has initiated coverage on Tyra Biosciences (TYRA) with a "peer perform" recommendation. This suggests that the firm expects Tyra Biosciences to perform in line with its industry peers.
TYRA Initiates Coverage On Wolfe Research -- Rating Set to Peer Perform
Wolfe Research has initiated coverage of Tyra Biosciences (TYRA) with a "Peer Perform" rating, indicating expectations for its stock to perform in line with its industry peers. No price target has been set, reflecting potential uncertainties. The company, a clinical-stage biotechnology firm with a $2.12 billion market cap, has a GF Score of 30/100, highlighting strong financial health but weaknesses in profitability and growth.
Wolfe Research initiates Tyra Biosciences stock at Peerperform By Investing.com
Wolfe Research initiated coverage on Tyra Biosciences (NASDAQ:TYRA) with a Peerperform rating, focusing on its selective FGFR3 inhibitor for bladder cancer and achondroplasia. The firm anticipates dabogratinib could achieve significant complete response rates for bladder cancer and contribute to revenue by 2029. Despite the stock appearing overvalued relative to its Fair Value, the company boasts a strong balance sheet with high liquidity, and analysts largely maintain a Strong Buy consensus.
Is Tyra Biosciences’ (TYRA) Dabogratinib 3×3 Focus Reframing Its Risk Reward Profile?
Tyra Biosciences (TYRA) reported a wider net loss of US$39.31 million in Q1 2026, with a basic loss per share of US$0.64. However, the company highlighted progress in three Phase 2 trials for its lead candidate, dabogratinib, and a strong cash balance of US$383.5 million, providing a runway into the second half of 2028. This focused "dabogratinib 3x3" strategy, targeting three FGFR3-driven indications, is central to the company's investment narrative, with upcoming clinical readouts serving as key catalysts, though the stock's valuation remains a point of exploration for investors.
Is Tyra Biosciences’ (TYRA) Dabogratinib 3×3 Focus Reframing Its Risk Reward Profile?
Tyra Biosciences reported a wider net loss of US$39.31 million in Q1 2026 but highlighted progress in three Phase 2 trials for its lead candidate, dabogratinib, and a cash balance of US$383.5 million to fund operations into mid-2028. The company's "dabogratinib 3x3" strategy focuses resources on three FGFR3-driven indications, which management believes will shape its path towards drug registration and commercialization. While the long cash runway and rising losses have implications, the stock currently has only one fair value estimate from the Simply Wall St Community.
(TYRA) and the Role of Price-Sensitive Allocations
Tyra Biosciences Inc. (NASDAQ: TYRA) is currently experiencing strong positive sentiment in the near term, with resistance being tested. AI models have generated three distinct institutional trading strategies-Position Trading, Momentum Breakout, and Risk Hedging-tailored to different risk profiles. The stock shows strong signals for both near-term and long-term horizons, while appearing neutral in the mid-term.
Commodore Capital (TYRA) reports 2.48M-share, 4.2% stake (Mar 31, 2026)
Commodore Capital entities and two managing partners beneficially own 2.48 million shares, representing a 4.2% stake, in Tyra Biosciences (TYRA) as of March 31, 2026. The Schedule 13G/A filing indicates that Commodore Capital LP and Commodore Capital Master LP are the beneficial owners, with Michael Kramarz and Robert Egen Atkinson exercising investment discretion. The filing categorizes the impact and sentiment as neutral, and it does not disclose any immediate plans for buying or selling shares.
Janus Henderson (TYRA) discloses 3.89M shares; 7.2% stake (Schedule 13G/A)
Janus Henderson Group plc has disclosed a 7.2% stake in Tyra Biosciences, Inc. (TYRA), totaling 3,890,589 common shares, via an amended Schedule 13G/A filing. The filing indicates that Janus Henderson's Asset Managers exercise shared voting and dispositive power over these shares on behalf of Managed Portfolios, while disclaiming any rights to dividends or sale proceeds. No individual Managed Portfolio holds more than 5% of TYRA's common stock, and the filing emphasizes that the ownership is a passive holding, not intended to influence control of the issuer.
Todd Harris reports 2.91M shares in Tyra Biosciences (TYRA)
Todd Harris has reported beneficial ownership of 2,913,342 shares in Tyra Biosciences (TYRA), representing a 4.8% stake in the company as of March 31, 2026. This stake includes both directly held shares and stock options exercisable within 60 days. The filing confirms Harris has sole voting and dispositive power over these shares, with analysts noting the neutral impact due to a significant portion deriving from exercisable options rather than solely held shares.
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $37
BofA Securities analyst Jason Zemansky has maintained a "Buy" rating for TYRA BIOSCIENCES, INC. (TYRA.US) and kept the target price at $37. According to TipRanks data, Zemansky has a 56.7% success rate and an average return of 19.7% over the past year. This report emphasizes that the information is for informational purposes only and not investment advice.
Tyra Biosciences (NASDAQ:TYRA) Issues Quarterly Earnings Results
Tyra Biosciences (NASDAQ:TYRA) reported a Q1 EPS of ($0.64), missing the consensus estimate of ($0.60). The company is advancing its lead FGFR3 inhibitor dabogratinib across multiple late-stage opportunities under its "Dabo 3x3" strategy, with programs potentially being first-in-class or best-in-class, particularly highlighting the upcoming SURF302 readout for intermediate-risk NMIBC. TYRA's stock traded up on Wednesday, and institutional investors have recently modified their holdings, while Wall Street analysts maintain a "Moderate Buy" rating with an average price target of $46.50.
Tyra Biosciences Q1 Net Loss Widens
This article reports on Tyra Biosciences' first-quarter financial results, indicating a widening net loss compared to the previous year. The company's net loss per share also increased, while total operating expenses saw a significant rise. Despite this, the company maintains a strong cash position.
TD Cowen Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating
TD Cowen has reaffirmed its Buy rating on TYRA BIOSCIENCES, INC. (TYRA.US). This continued endorsement suggests the firm's positive outlook on the company's stock.
Earnings Flash (TYRA) Tyra Biosciences Posts Q1 Net Loss $0.64 a Share, vs. FactSet Est of $0.59 Loss
Tyra Biosciences (TYRA) reported a Q1 net loss of $0.64 per share, which is wider than the FactSet estimate of a $0.59 loss per share. The company is a clinical-stage biotechnology firm focused on developing precision medicines for FGFR biology, with its lead candidate TYRA-300 being a selective FGFR3 inhibitor currently in clinical development. The article also lists recent news and analyst ratings for the company.
Tyra Biosciences reports Q1 2026 net loss $39.3M, cash $383.5M; advances dabogratinib programs
Tyra Biosciences reported a net loss of $39.3 million for Q1 2026, alongside $383.5 million in cash, cash equivalents, and marketable securities, providing a financial runway into the second half of 2028. The company is advancing multiple Phase 2 programs for oral dabogratinib, including studies for LG-UTUC, IR NMIBC, and achondroplasia, with initial data readouts expected in 2026-2027. R&D and G&A expenses increased as the company progressed its clinical pipeline.
[8-K] Tyra Biosciences, Inc. Reports Material Event
Tyra Biosciences reported a wider net loss of $39.3 million in Q1 2026, compared to $28.1 million a year prior, due to increased spending on advancing its pipeline, particularly for Phase 2 trials of oral dabogratinib. The company's R&D expenses rose to $33.5 million, reflecting its "dabogratinib 3x3" strategy focused on FGFR3-driven diseases, including urologic cancers and achondroplasia. Despite the increased expenses, Tyra maintained a strong cash position of $383.5 million, expected to fund operations into the second half of 2028, and anticipates several key clinical data readouts in the coming months.
Tyra Biosciences 1Q 2026: Net income $(39.3M), EPS $(0.64) — 10-Q Summary
Tyra Biosciences reported a wider net loss of $(39.3M) for Q1 2026, compared to $(28.1M) in Q1 2025, with diluted EPS of $(0.64) reflecting increased research and development investment across multiple clinical programs. The company advanced its lead candidate dabogratinib into three Phase 2 trials and continued progress on other pipeline initiatives, including the BEACH301 pediatric program and the SNÅP precision platform. Tyra Biosciences had $383.5M in cash and investments at the end of March 2026, expected to fund operations into the second half of 2028.
[144] Tyra Biosciences, Inc. SEC Filing
This article reports on a Form 144 SEC filing by Tyra Biosciences, Inc. (TYRA) related to a proposed sale of securities. The filing details include information about the filer, the issuer, the class of securities being sold (Common stock), the aggregate market value, and previous sales by Daniel Bensen. The filing also mentions the relationship of the seller to the issuer and provides a detailed breakdown of the acquisition of the securities.
Farallon funds disclose multi‑percent TYRA holdings (TYRA)
Farallon-related entities have filed an Amendment No. 1 to their Schedule 13G/A, updating their shared beneficial ownership in Tyra Biosciences, Inc. (TYRA) Common Stock. The filing reveals various Farallon funds and affiliated individuals holding stakes ranging from 0.1% to 6.6% of TYRA shares. The aggregated beneficial ownership reflects direct holdings by Farallon Funds, with general partners and individual reporting persons potentially deemed beneficial owners, while explicitly disclaiming affirmative group status.
Tyra Biosciences earnings on deck as bladder cancer data looms
Tyra Biosciences is set to report its first-quarter earnings, with analysts anticipating wider losses but maintaining "Buy" ratings due to the upcoming critical Phase 2 data for dabogratinib, its lead bladder cancer drug. The market is keenly awaiting initial three-month complete response data from the SURF302 trial by late Q2 2026, which is expected to be a significant catalyst for the stock. Despite projected losses, the company holds a strong cash position to fund its pipeline, including late-stage studies for bladder cancer and achondroplasia.
Tyra Biosciences earnings on deck as bladder cancer data looms
Tyra Biosciences is set to report Q1 earnings with analysts expecting wider losses but maintaining a "Buy" rating due to the anticipated release of Phase 2 data for its lead drug, dabogratinib, in bladder cancer. This data, expected by mid-2026, is considered a critical inflection point, with high hopes for the drug's oral efficacy and improved safety profile compared to existing treatments. Investors are closely watching for updates on the SURF302 trial and burn rate guidance.
Tyra Biosciences Q4 Loss Widens
This article reports that Tyra Biosciences experienced a wider loss in the fourth quarter. It provides an update on the company's financial performance.
Tyra Biosciences (NASDAQ: TYRA) CMO awarded RSUs and 85,000-share option
Tyra Biosciences' Chief Medical Officer, Douglas J. Warner, was granted 25,000 Restricted Stock Units (RSUs) and a stock option for 85,000 shares as part of his compensation. These awards, granted on May 5, 2026, will vest over several years subject to his continuous service, with the stock option having an exercise price of $33.93 per share. This transaction is classified as compensation and not an open-market purchase or sale.
Tyra Biosciences to Participate in Upcoming Investor Conferences
Tyra Biosciences, Inc. announced its participation in several upcoming investor conferences in May and June 2026, including the BofA Securities Health Care Conference, TD Cowen's 7th Annual Oncology Innovation Summit, and the Jefferies Global Healthcare Conference. The company will conduct virtual and hybrid fireside chats and one-on-one investor meetings to discuss its progress in developing precision medicines targeting FGFR biology. Webcasts of the presentations will be available on the company's website.
Tyra Biosciences (TYRA) awards CFO Alan Fuhrman RSUs and 67,000 options
Tyra Biosciences has granted Chief Financial Officer Alan Fuhrman new equity awards, including 20,000 restricted stock units (RSUs) and options on 67,000 shares of common stock. The RSUs will vest in four equal annual installments starting May 5, 2027, while the stock options, priced at $33.93 per share, will vest monthly over four years and expire on May 4, 2036. Following these grants, Fuhrman directly owns 36,164 shares of common stock, including the RSUs, with all awards contingent on his continuous service to the company.
Tyra Biosciences (TYRA) awards RSUs and 28,000-share option to VP
Tyra Biosciences (TYRA) announced that its VP of Finance, Yuliya Rueb, received 8,333 restricted stock units (RSUs) and an option to purchase 28,000 shares of common stock. The RSUs vest over four years, while the stock option, with an exercise price of $33.93, vests monthly over 48 months. Following these grants, Rueb directly holds 43,354 shares of common stock, including RSUs.
Three Tyra Biosciences investor events start May 13, with webcasts
Tyra Biosciences (Nasdaq: TYRA) announced its participation in three upcoming investor conferences in May and June 2026. The company will be featured in virtual fireside chats and one-on-one investor meetings at the BofA Securities Health Care Conference, TD Cowen Oncology Innovation Summit, and Jefferies Global Healthcare Conference. Live webcasts and replays for these events will be accessible via the "For Investors" page on the Tyra Biosciences website.
Tyra Biosciences to Participate in Upcoming Investor Conferences
Tyra Biosciences, a clinical-stage biotechnology company, announced its participation in three upcoming investor conferences: the BofA Securities Health Care Conference, TD Cowen’s 7th Annual Oncology Innovation Summit, and the Jefferies Global Healthcare Conference. The company will present its pipeline of precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology, including lead candidate dabogratinib and other investigational treatments. Live webcasts of these presentations will be available on the "For Investors" page of their website.
How TYRA-300 Bladder Cancer Data and New Trial Partnership Will Impact Tyra Biosciences (TYRA) Investors
Tyra Biosciences recently released positive interim Phase 1/2 data for TYRA-300 in metastatic urothelial carcinoma, showing an objective response rate and favorable safety. Concurrently, the company announced a new SURF302 trial partnership with the University of Kansas Medical Center, reinforcing confidence in its FGFR3-focused approach. While these developments are encouraging, investors are still evaluating the therapy against competitors, with future readouts from the SURF301 and SURF302 programs remaining key catalysts.
How TYRA-300 Bladder Cancer Data and New Trial Partnership Will Impact Tyra Biosciences (TYRA) Investors
Tyra Biosciences recently announced interim Phase 1/2 data for TYRA-300 in metastatic urothelial carcinoma, showing positive responses and a favorable safety profile. The company also formed a new SURF302 trial partnership, reinforcing confidence in its FGFR3-focused approach. While the data is encouraging, investors are weighing it against the company's financial risks and the need for further trial validation.
Responsive Playbooks and the TYRA Inflection
Tyra Biosciences Inc. (NASDAQ: TYRA) shows weak near-term sentiment but strong long-term potential, with a mid-channel oscillation pattern observed. AI models have generated three trading strategies—Long Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The stock exhibits divergent sentiment across various time horizons, suggesting choppy market conditions.
Tyra Biosciences initiates partnership with KUMedCenter to advance SURF302 bladder cancer trial
Tyra Biosciences has partnered with the University of Kansas Medical Center to support its SURF302 clinical trial, which focuses on bladder cancer research. The collaboration aims to combine medical expertise with innovative clinical strategies, led by John A. Taylor, III, MD, MS, and the KUMedCenter team. This partnership is expected to drive significant progress in developing new bladder cancer therapies.
Achondroplasia Pipeline Expands as 15+ Pharma Companies Advance Targeted Therapies for Dwarfism, Finds DelveInsight | QED Therapeutics, Ascendis Pharma, Tyra Biosciences, BridgeBio
The achondroplasia treatment pipeline is expanding rapidly, with over 15 pharmaceutical companies advancing targeted therapies for dwarfism. Key players like QED Therapeutics (BridgeBio), Ascendis Pharma, and Tyra Biosciences are developing promising drugs such as infigratinib, navepegritide (TransCon CNP), and TYRA-300, which are in various stages of clinical trials, including Phase III. These emerging therapies aim to address the root genetic causes of achondroplasia by targeting FGFR3 and CNP pathways to improve skeletal development and overall quality of life.
TYRA SEC Filings - Tyra Biosciences, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Tyra Biosciences SEC filings, including annual 10-K reports, quarterly 10-Q reports, 8-K material event forms, and insider trading forms. Tyra Biosciences is a clinical-stage biotechnology company focusing on precision medicines. The site offers AI-powered summaries to highlight key disclosures, clinical trial milestones, and financial commentary.
Tyra Biosciences faces earnings test ahead of key trial data
Tyra Biosciences is set to report its first-quarter results, with investors keenly focused on updates regarding its dabogratinib strategy before critical Phase 2 data expected by the end of June. Analysts predict a loss of 59 cents per share on zero revenue, and all 13 analysts covering the stock rate it a Strong Buy with a consensus price target of $51.24. The company's cash position of $256 million, supplemented by a recent $126 million sale, is expected to fund operations into 2028, and a successful dabogratinib trial could significantly boost its commercial prospects.
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of "Moderate Buy" by Analysts
Tyra Biosciences, Inc. (NASDAQ:TYRA) has received an average recommendation of "Moderate Buy" from twelve analysts, with an average 12-month price target of $46.50. This comes despite a director selling a significant portion of her holdings and the company missing its quarterly EPS estimates. Institutional investors, however, have largely increased their positions in the company, which continues to focus on developing small-molecule therapies for genetically defined cancers.
Does Tyra Biosciences (TYRA) Board Refresh and Dabogratinib Spotlight Reframe Its Pipeline Credibility?
Tyra Biosciences recently appointed Habib Dable to its Board of Directors and Guggenheim Securities initiated coverage, highlighting the potential of dabogratinib. While Dable's experience strengthens the leadership, the company's investment narrative still largely depends on trial readouts and financing without excessive shareholder dilution, given significant annual losses and no revenue. Investors should consider Tyra's reliance on future trial progress and potential dilution risks.
Does Tyra Biosciences (TYRA) Board Refresh and Dabogratinib Spotlight Reframe Its Pipeline Credibility?
Tyra Biosciences recently appointed Habib Dable to its Board of Directors and received optimistic coverage from Guggenheim Securities regarding its lead candidate, dabogratinib. The company's investment narrative heavily relies on the success of its FGFR-focused pipeline and its ability to fund studies without significant shareholder dilution. While Dable's appointment strengthens leadership, clinical and financing milestones remain the primary short-term catalysts and risks for investors.
TYRA BIOSCIENCES, INC. | SCHEDULE 13G/A: Others
This document indicates a Schedule 13G/A filing for TYRA BIOSCIENCES, INC., signaling an update to a previous beneficial ownership report by a significant shareholder. The filing type, "Others," suggests the amendment comes from a category other than institutional investors or passive investors. The document itself is the core content of this filing.
Guggenheim Securities Issues Buy Rating for Tyra Biosciences
Guggenheim Securities has initiated coverage of Tyra Biosciences (TYRA) with a Buy rating and a $54 price target, citing the strong potential of its lead drug candidate, dabogratinib, for treating various patient groups. The firm believes successful clinical outcomes could lead to substantial upside for the stock. Additionally, Tyra Biosciences recently appointed Habib Dable to its Board of Directors to guide the advancement of its FGFR3-targeted pipeline and commercial development.
Canaan reports 750,000 shares in Tyra Biosciences (NASDAQ: TYRA)
Canaan-affiliated investors have amended their Schedule 13G/A filing, reporting beneficial ownership of 750,000 shares in Tyra Biosciences (NASDAQ: TYRA), which represents a 1.4% stake. This filing clarifies that Canaan XI L.P. and Canaan Partners XI LLC have sole voting and dispositive power over these shares. Additionally, Canaan 2020+ Co-Investment L.P. - Series 7 and its general partner no longer beneficially own any shares as of March 31, 2026.
Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib
Guggenheim Securities has initiated coverage of Tyra Biosciences, Inc. (TYRA) with a Buy rating and a $54 price target, citing the therapeutic potential of its lead drug candidate, dabogratinib. The firm believes the drug could have significant upside if successful in various patient groups and disease areas. Furthermore, Tyra Biosciences recently appointed Habib Dable, a biopharmaceutical industry veteran, to its Board of Directors to help advance its FGFR3-targeted pipeline.
Understanding the Setup: (TYRA) and Scalable Risk
This article analyzes Tyra Biosciences Inc. (NASDAQ: TYRA), highlighting a positive near-term sentiment within a long-term strength context. It identifies an exceptional 56.9:1 risk-reward setup, targeting a 16.2% gain against a 0.3% risk. The report also details institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Top 10 AI-Powered Biotech Stocks to Buy Right Now
This article highlights Tyra Biosciences, Inc. (NASDAQ: TYRA) as a top AI-powered biotech stock to consider. Guggenheim Securities initiated coverage with a Buy rating and a $54 price target, citing its promising lead drug candidate, dabogratinib. The company also strengthened its leadership with the addition of Habib Dable to its Board of Directors, bringing extensive biopharmaceutical industry experience.
Tyra Biosciences (TYRA) director Dable Habib J files Form 3 showing no share ownership
Tyra Biosciences, Inc. director Dable Habib J has filed an initial Form 3 with the SEC, reporting no beneficial ownership of the company's securities. This filing indicates that he holds zero shares in Tyra Biosciences at the time of the report. A Form 3 is an initial statement of beneficial ownership required when an individual becomes an insider (officer, director, or major shareholder) in a company.
44,400 Tyra Biosciences (TYRA) stock options granted to director Dable
Tyra Biosciences director Habib J. Dable has been granted 44,400 stock options with an exercise price of $35.12 per share, expiring on April 15, 2036. These options will vest monthly in 36 equal installments, contingent on his continued service to the company. This transaction is a compensation-related award rather than an open-market purchase or sale.
